If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-03-01. Numbers and descriptions here follow the published literature rather than marketing material.
Because epitalon has no pharmacopoeial monograph, quality assessment depends on supplier documentation and independent testing. Certificates of analysis typically report a purity figure from a single chromatographic run, a measured mass and sometimes an appearance description, but methods and acceptance criteria are not harmonised across vendors. Third-party laboratories can repeat identity and purity measurements, and mismatches between labelled and measured peptide content have been described for research peptides generally. What constitutes adequate identity confirmation for a molecule of this size stays an open question, since mass agreement alone does not separate closely related sequences.
Identity testing for epitalon relies on reversed-phase high-performance liquid chromatography for purity and mass spectrometry for mass confirmation. Because the sequence contains no tryptophan or tyrosine, ultraviolet detection at 280 nanometres is insensitive, so chromatographic methods usually monitor absorbance near 214 nanometres, where the peptide backbone absorbs. Electrospray ionisation or matrix-assisted laser desorption/ionisation then checks the intact mass against the expected value near 390 daltons. Peptide mapping or amino acid analysis after acid hydrolysis can supplement these measurements, although such confirmatory work is seldom reported on commercial certificates of analysis.
Stability of the tetrapeptide follows ordinary peptide chemistry rather than any unusual structural feature. The aspartate-glycine pair is prone to aspartimide formation under mildly basic or neutral conditions, and deamidation can follow, altering both mass and chromatographic retention. Dry lyophilised powder kept at or below minus twenty degrees Celsius is the usual handling recommendation, with repeated freeze-thaw cycles avoided. Once dissolved in neutral aqueous buffer, degradation proceeds over days to weeks depending on pH and temperature, while acidic conditions generally slow the aspartimide route. A formal stability-indicating study has not been published in the indexed literature.
Material sold for research use varies widely in documented quality. A useful verification package includes a certificate of analysis that states peptide content rather than only net weight, the chromatographic method and column used, and a mass spectrum consistent with the expected mass. Independent testing by a third-party laboratory is occasionally reported. Statements of identity resting only on a supplier label provide little assurance, and the gap between nominal mass and actual peptide content can be substantial once counterions and residual water are counted.
Peptides of this size are generally stable as dry solids but degrade in solution over time. The principal routes are hydrolysis of the peptide backbone and oxidation, with hydrolysis favoured by elevated temperature and extreme pH. Aqueous solutions held at room temperature can show measurable loss of purity within days, while frozen aliquots are considerably more durable. Because the sequence contains neither cysteine nor methionine, oxidation is less of a concern than for many other peptides, but pH control during handling still matters.
Typical storage for the lyophilized powder is −20 °C or lower, in a sealed container protected from light and moisture. Hygroscopic material should be allowed to equilibrate to room temperature before the vial is opened, which limits condensation on the contents. Working solutions are commonly divided into single-use aliquots and frozen to avoid repeated freeze-thaw cycles. Dilute solutions are more prone to adsorption onto plastic surfaces and to loss during filtration, so procedures that minimize transfers and use low-binding labware are preferable.
| Property | Value | Notes |
|---|---|---|
| Analytical method | Reversed-phase HPLC | Purity determination, typically 214 nm |
| Mass confirmation | ESI or MALDI mass spectrometry | Compared with mass near 390 Da |
| Common synonyms | Epitalon, epithalon, AEDG | Naming differs between suppliers |
| Storage temperature | −20 °C or lower | Lyophilised powder, kept desiccated |
| Solution stability | Limited in neutral aqueous buffer | Aspartimide and hydrolysis pathways |
No national medicines regulator has approved epitalon as a therapeutic product. It is generally distributed as a research chemical, and in some jurisdictions selling peptides for human consumption without approval is restricted or prohibited. Certificates of analysis accompanying commercial material vary in which tests are performed, and independent verification of identity and purity is uncommon. Statements about anti-ageing or disease-prevention benefits on vendor pages are marketing claims rather than regulatory findings, a distinction that shapes how the compound is discussed in scientific and popular sources alike.
The most frequently cited laboratory finding is that AEDG increased telomerase activity and extended telomere length in cultured human somatic cells. That work used fetal fibroblast strains and reported changes in enzyme activity alongside altered division counts. Replication by unrelated groups has been limited, and the published record is largely a single-laboratory series rather than a multi-centre programme. The result supports a hypothesis about peptide influence on gene expression in cell culture; it does not by itself establish an effect on telomere length in living animals or in people.
Animal and clinical reports appear mainly in Russian-language journals from the 1990s and 2000s, covering endpoints such as melatonin rhythm, lifespan in aged rodents, and retinal function. Many of these papers involve small groups, lack blinding or placebo comparison, and are difficult to retrieve through indexed databases. Review articles published in English generally summarise the claims without reanalysing the underlying data. Because no large randomised trial exists, the clinical importance of these reported effects stays unresolved and is properly described as an open question.
Identity is normally established by reversed-phase high-performance liquid chromatography combined with mass spectrometry, a pairing that separates components and confirms molecular mass at once. Purity is quoted as a percentage from the chromatogram, and figures above ninety-five percent are a frequent commercial specification. Amino acid analysis or sequencing supplies further confirmation when required. Because many short peptides behave similarly under chromatography, retention time alone does not establish sequence; the mass measurement is what separates one tetrapeptide from another, and certificates should report both.
Short peptides such as AEDG are normally supplied as a freeze-dried solid and are kept dry, cold, and shielded from light. Holding at minus twenty degrees Celsius is common for the long term, while a refrigerator suffices for brief periods before use. The material takes up moisture to some degree, so containers should stay sealed and be allowed to reach room temperature before opening, which limits condensation on the contents. Repeated warming and cooling of a single container is discouraged because it admits water and can lower the amount of intact peptide.
Dissolution is usually performed in water or a suitable aqueous buffer, and the resulting liquid is divided into single-use portions before freezing. Freeze-thaw cycling is a recognised source of loss for short peptides, since each cycle can encourage aggregation or adsorption onto container walls. Working solutions are generally kept cold and used within a short window, although published stability data specific to epitalon are thin. Containers should be marked with concentration and date, and solutions examined for cloudiness before use.
The most widely cited claim is that epitalon activates telomerase and thereby extends telomere length. Supporting evidence comes largely from cultured human cells, where treatment was associated with increased telomerase activity and delayed replicative senescence. Telomerase activation is a biologically consequential effect, since the enzyme is largely silenced in most somatic cells. However, the route by which a short peptide would reach and act on the enzyme's regulatory machinery has not been established. Independent replication in human trials is scarce, so the link between cell-culture observations and whole-body aging remains an open question.
Human data are limited to small studies, often without the randomization, blinding, or control groups expected in contemporary clinical research. Reported outcomes have included changes in melatonin levels, immune markers, and subjective measures, but sample sizes were generally too small to support firm conclusions. Some reviews treat the peptide as promising while noting methodological weaknesses; others question whether the observed effects are specific. The compound is frequently discussed in longevity-focused communities, where enthusiasm often outpaces the published evidence. Separating established findings from speculation is therefore important when reading summaries of this research.
Epitalon emerged from research conducted in Saint Petersburg by Vladimir Khavinson and colleagues, who studied short peptides as potential regulators of aging. The work built on epithalamin, a pineal gland extract reported to influence neuroendocrine function. Epitalon was designed as a synthetic counterpart with a defined sequence, allowing reproducible experiments that extracts could not support. Early publications described effects on melatonin rhythms and lifespan in animal models. These findings circulated mainly in Russian-language journals during the 1990s, which limited their visibility among English-speaking researchers.
Laboratory handling begins with dissolution of the lyophilized powder in water or a suitable aqueous buffer. The dry solid is the more stable form, so stock solutions are generally prepared only when required and kept cold afterwards. Repeated freezing and thawing of a solution is avoided because it encourages aggregation and gradual loss of the intact chain. Diluents and containers are selected to limit adsorption of a short peptide onto plastic surfaces and to reduce microbial growth in aqueous preparations.
Stability depends strongly on pH, temperature and the presence of oxygen and trace metals. Cleavage of the backbone proceeds faster under neutral to alkaline conditions, whereas acidic solutions tend to slow that reaction. The aspartate and glutamate side chains can undergo deamidation or imide formation over time, generating closely related impurities. Published stability data specific to epitalon are sparse, so the usable life of a given solution is best regarded as an open question that depends on buffer composition, concentration and storage temperature.
Somorjai (born 1935), 1998 Wolf Prize in Chemistry Georg Ernst Stahl (1659–1734), Important work on fermentation Wendell Meredith Stanley (1904–1971), 1946 Nobel Prize in Chemistry Jean Servais Stas (1813–1891), Belgian analytical chemist Branko Stanovnik (born 1938), chemist Hermann Staudinger (1881–1965), polymer chemist, 1953 Nobel Prize in Chemistry Harry Steenbock (1886–1967), American biochemist, worked on ultraviolet irradiation William Howard Stein (1911–1980), 1972 Nobel Prize in Chemistry Thomas A. Steitz (1940–2018), 2009 Nobel Prize in Chemistry Douglas Stephan, Frustrated Lewis Pairs Rose Stern (1869–1953), first British woman member of the Royal Institute of Chemistry Alfred Stock (1876–1946), German inorganic chemist, known for work in mercury poisoning Brian Stoltz (born 1970), award-winning American organic chemist. Fraser Stoddart (1942–2024), Scottish chemist, a pioneer in the field of the mechanical bond Molly Shoichet, award-winning Canadian biomedical engineer known for her work in tissue engineering. She is the only person to be a fellow of the three National Academies in Canada F. Gordon A. Stone (1925–2011), British inorganic chemist S. Donald Stookey (1915–2014), American glass and ceramic chemist Gilbert Stork (1921–2017), 1995/6 Wolf Prize in Chemistry Friedrich August Kekulé von Stradonitz (1829–1896), German organic chemist, principal founder of chemical structure Yellapragada Subbarow (1895-1948), Indian biochemist known for discovery of ATP and synthesis of many new ground breaking compounds James B.
Peritoneal ligament: a fold of peritoneum or other membranes. Fetal remnant ligament: the remnants of a fetal tubular structure. Periodontal ligament: a group of fibers that attach the cementum of teeth to the surrounding alveolar bone.
== Treatment == CTD is difficult to treat because the transporter responsible for transporting creatine to the brain and muscles is defective. Affected individuals have sufficient amounts of creatine, but it cannot get to the tissues where it is needed. Studies in which oral creatine monohydrate supplements were given to patients with CTD found that patients did not respond to treatment. Patients with CTD are unresponsive to oral creatine monohydrate supplements because regardless of the amount of creatine they ingest, the creatine transporter is still defective, and therefore creatine is incapable of being transported across the BBB. Therapeutic approaches that are currently in development include dodecyl creatine ester (DCE) for intranasal creatine delivery, pharmacochaperones to aid in rescuing misfolded transporter, and gene therapy to compensate for the mutated SLC6A8 gene.
==== Agonists ==== Agmatine (putative endogenous ligand at I1; also interacts with NMDA, nicotinic, and α2 adrenoceptors) Apraclonidine (α2 adrenoceptor agonist) 2-BFI (I2 agonist, NMDA antagonist) Cimetidine (I1 agonist, H2 receptor antagonist) Clonidine (I1 agonist, α2 adrenoceptor agonist) LNP-509 LNP-911 7-Me-marsanidine Dimethyltryptamine mCPP Moxonidine Oxymetazoline (I1 agonist, α1 adrenoceptor agonist, α2 partial agonist) Rilmenidine S-23515 S-23757 Tizanidine
== Further reading == Moskin, Julia (August 19, 2014). "Brisket Is Worth the Wait". The New York Times. Retrieved March 17, 2015. Green, Aliza (2005). Field Guide to Meat. Philadelphia: Quirk Books. ISBN 1-931686-79-3.
Sources: en.wikipedia.org
The protein in cow's milk is approximately 20% whey and 80% casein. The protein in human milk is approximately 60% whey and 40% casein. The protein fraction in whey constitutes approximately 10% of the total dry solids in whey. This protein is typically a mixture of beta-lactoglobulin (~65%), alpha-lactalbumin (~25%), bovine serum albumin (~8%) (see also serum albumin), and immunoglobulins. The third largest fragment of whey protein isolate derived from sweet whey is glycomacropeptide or GMP. However, GMP lacks the secondary structure necessary for it to be classified as a protein and is considered a long amino acid chain. These peptides are all soluble in water in their native forms.
=== Sources === Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds. (2003). Fitzpatrick's Dermatology in General Medicine (6th ed.). McGraw-Hill. ISBN 978-0-07-138076-8. James W, Berger T, Elston D (2005). Andrews' Diseases of the Skin: Clinical Dermatology (10th ed.). Saunders. ISBN 978-0-7216-2921-6. Rapini RP, Bolognia JL, Jorizzo JL (2007). Dermatology: 2-Volume Set. St. Louis: Mosby. ISBN 978-1-4160-2999-1.
=== Charge detection mass spectrometry === Most mass spectrometers measure the mass-to-charge ratio; the actual mass can be found only if the charge is known. For smaller molecules the charge can be determined from the spacing of isotope peaks, but for very large biomolecules and particles (in the megadalton range) resolution may not be adequate to separate isotope peaks, and thus the mass cannot be determined. In charge detection mass spectrometry (CDMS), the charge of an individual ion/particle is measured directly (alongside its mass-to-charge ratio) and therefore the true mass is known. It is a single-particle technique, but to produce more precise and accurate results, the data from many individually-measured ions can be combined.
In Syria, most Druze reside in the As-Suwayda Governorate, which encompasses almost all of Jabal al-Druze. This governorate is unique in Syria as it has a Druze majority. Additionally, it has integrated Christian communities that have long coexisted harmoniously with the Druze in these mountain. In the 1980s Druze made up 87.6% of the population, Christians (mostly Greek Orthodox) 11% and Sunni Muslims 2%. In 2010, the As-Suwayda governorate has a population of about 375,000 inhabitants, Druze made up 90%, Christians 7% and Sunni Muslims 3%. Due to low birth and high emigration rates, Christians proportion in As-Suwayda had declined. The Druze form a majority in the Jabal Hauran, which is part of the al-Suwayda Governorate. There is a significant Christian population, both Greek Orthodox and Greek Catholic (Melkite), in the Hauran region as a whole, though most Christians are concentrated in the towns and villages straddling the western foothills of Jabal Hauran. Most of the Christians of Jabal Hauran are descents of the Ghassanids (Arab tribe). A major component of the Azd tribal confederation, the Ghassanids established themselves in Arabia Province and like the Salihids, embraced Christianity. The Byzantine era in the Hauran was marked by the dual processes of rapid Arabization and the growth of Christianity. According to the historian Kamal al-Shofani "Christians inhabited the region before the Druze, and some of them came to Jabal al-Druze (Mountain of the Druze) at the end of the 17th century, fleeing Ottoman oppression".
=== Sensory perception === This parameter measures a patient's ability to detect and respond to discomfort or pain that is related to pressure on parts of their body. The ability to sense pain itself plays into this category, as does the level of consciousness of a patient and therefore their ability to cognitively react to pressure-related discomfort.
Sources: en.wikipedia.org
=== By-products of microorganisms === The lactic acid bacteria (LAB) produce lactic acid, hydrogen peroxide, and carbon dioxide as by-products during metabolism. Lactic acid quickly lowers the pH, creating an acidic environment that is uninhabitable for most other microorganisms that survived salting. This also modifies the flavor of sub-ingredients and can increase the nutritive value of the raw materials, as the microbial community in the fermentation process can synthesize B vitamins and hydrolyze cellulose in plant tissues to free nutrients that are normally indigestible by the human gastrointestinal tract. Hydrogen peroxide is formed by the oxidation of reduced nicotinamide adenine dinucleotide (NADH) and provides an antibiotic to inhibit some undesirable microorganisms. Carbon dioxide functions as a preservative, flushing out oxygen to create an anaerobic environment, as well as creating the desired carbonation in the final product.
==== Genomic context methods ==== The Rosetta Stone or Domain Fusion method is based on the hypothesis that interacting proteins are sometimes fused into a single protein in another genome. Therefore, we can predict if two proteins may be interacting by determining if they each have non-overlapping sequence similarity to a region of a single protein sequence in another genome. The Conserved Neighborhood method is based on the hypothesis that if genes encoding two proteins are neighbors on a chromosome in many genomes, then they are likely functionally related (and possibly physically interacting). The Phylogenetic Profile method is based on the hypothesis that if two or more proteins are concurrently present or absent across several genomes, then they are likely functionally related. Therefore, potentially interacting proteins can be identified by determining the presence or absence of genes across many genomes and selecting those genes which are always present or absent together.
== Mass spectrometry-intensive TDP (MSi-TDP) == MSi-TDP (sometimes referred to as TD-MS) is a method of proteoform identification that uses a mass spectrometer to determine the mass of a species from the charge series of the resulting ions and obtain sequence information by selecting a single charge state ion for MS/MS analysis . The stated goal of MSi-TDP is to carry out proteoform analysis fully in the mass spectrometer using a variety of fragmentation methods (e.g. collision-induced dissociation, electron-capture dissociation or electron-transfer dissociation). Due to proteoform molecules taking up different numbers of H+ ions and forming multiple charge states, having multiple different proteoforms appearing in the mass spectrometer at the same time can create extremely complicated spectra that are difficult to deconvolute and analyse, while also having the potential for ion suppression that reduces signal and sensitivity. This is most effectively overcome by separating the different proteoforms, typically by tube gel electrophoresis and subsequent reversed phase chromatography, immediately prior to ionisation, to reduce the number of proteoforms entering the instrument at a particular moment. Therefore, like iTDP, effective sample/proteome fractionation is critical before MSi-TDP to ensure success of analyses within the limitations of the method. Thus, in contrast to BUP, MSi-TDP interrogates proteoform structure through measurement of an intact mass followed by direct ion dissociation in the gas phase.
The results tend to show that the experimental HLB of sucrose monoesters, composed of 100% of monoesters for purified products and around 70-80% for industrial blends, would be rather around 11-12 for short fatty chains (6 to 12 carbons) and around 10-11 for long fatty chains (14 to 18 carbons). These values would better describe their emulsifying behavior and would better make the correspondence with other families of surfactants. Notably, the experimental range of HLB of sucrose esters would not be so wide as the calculated HLB indicated on suppliers technical sheets, especially not as high as HLB 16. It is also important to point out the fact that in experiments, the residual amount of fatty acid (even less than 2% in weight) and the state of protonation of the latter has a significant effect on the phase properties and the emulsifying properties of sucrose esters, because the deprotonated fatty acid is highly surface active while the protonated fatty acid is not. This state of protonation has also an impact on the experimental determination of the HLB. The "wide range of HLB" currently defined for sucrose esters marketed blends, which is supposed to spread up to 16, should be considered with a critical point of view at the light of these observations. While the use of the different grades of sucrose esters is well documented in some applications, notably for food formulations, clarifying their HLB scale on an experimental basis will help their implementation in new applications not yet documented.
To solve this problem, contrast agents with disulfide, reversible bond between metal chelate and transduction moiety enhance the cell-associated retention. The disulfide bond is reduced by the target cell environment and the metal chelate remains trapped in the cytoplasm, increasing the retention time of chelate in the target cell.
Sources: en.wikipedia.org
The molecule lacks aromatic residues, so it absorbs weakly near 280 nanometres, the wavelength applied to many other peptides. The peptide bond absorbs strongly below 220 nanometres, making 214 nanometres a practical compromise. Gradient methods must therefore use mobile phases with low ultraviolet absorbance to keep the baseline clean.
Neutral and slightly basic aqueous conditions promote aspartimide formation at the aspartate-glycine step, often followed by deamidation. Elevated temperature and repeated freeze-thaw cycles accelerate the loss. Acidic solutions and dry lyophilised powder are comparatively stable over short periods.
No monograph exists in the United States Pharmacopeia or the European Pharmacopoeia, and no widely distributed certified reference standard is available. Purity and identity therefore rest on supplier methods that are not harmonised. This absence is the main reason reported purities are difficult to compare between sources.
The powder is normally kept at −20 °C or below in a sealed, moisture-protected container. Letting the vial reach room temperature before opening helps prevent condensation on the contents.